Dyax Corp. Company Profile (NASDAQ:DYAX)

About Dyax Corp. (NASDAQ:DYAX)

Dyax Corp. logoDyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:DYAX
  • CUSIP: 26746E10
  • Web: www.dyax.com
Average Prices:
  • 50 Day Moving Avg: $37.73
  • 200 Day Moving Avg: $29.05
  • 52 Week Range: $14.06 - $38.56
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -274.36
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -47.32%
  • Return on Equity: -14.86%
  • Return on Assets: -12.09%
Misc:
  • Average Volume: 3.62 million shs.
 

Frequently Asked Questions for Dyax Corp. (NASDAQ:DYAX)

What is Dyax Corp.'s stock symbol?

Dyax Corp. trades on the NASDAQ under the ticker symbol "DYAX."

How were Dyax Corp.'s earnings last quarter?

Dyax Corp. (NASDAQ:DYAX) posted its earnings results on Wednesday, October, 28th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm earned $24.70 million during the quarter, compared to analyst estimates of $24.96 million. Dyax Corp. had a negative net margin of 47.32% and a negative return on equity of 14.86%. The business's quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.01) EPS. View Dyax Corp.'s Earnings History.

Who are some of Dyax Corp.'s key competitors?

How do I buy Dyax Corp. stock?

Shares of Dyax Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dyax Corp.'s stock price today?

One share of Dyax Corp. stock can currently be purchased for approximately $38.41.


MarketBeat Community Rating for Dyax Corp. (NASDAQ DYAX)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Dyax Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dyax Corp. (NASDAQ:DYAX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Dyax Corp. (NASDAQ:DYAX)
Price Target History for Dyax Corp. (NASDAQ:DYAX)
Analysts' Ratings History for Dyax Corp. (NASDAQ:DYAX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/7/2015Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
11/9/2015Leerink SwannDowngradeOutperform -> Market Perform$37.00N/AView Rating Details
11/5/2015Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
11/2/2015Jefferies Group LLCDowngradeBuy -> Hold$37.00N/AView Rating Details
11/2/2015WedbushDowngradeOutperform -> NeutralN/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Dyax Corp. (NASDAQ:DYAX)
Earnings by Quarter for Dyax Corp. (NASDAQ:DYAX)
Earnings History by Quarter for Dyax Corp. (NASDAQ DYAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/28/2015Q315($0.08)($0.08)$24.96 million$24.70 millionViewN/AView Earnings Details
7/29/2015Q215($0.04)($0.06)$23.40 million$264.00 millionViewListenView Earnings Details
4/29/2015Q115($0.05)($0.05)$21.79 million$20.40 millionViewN/AView Earnings Details
2/24/2015Q414($0.04)($0.02)$19.90 million$26.00 millionViewN/AView Earnings Details
10/28/2014Q314($0.06)($0.01)$15.70 million$22.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.05)($0.02)$14.13 million$19.59 millionViewN/AView Earnings Details
4/30/2014Q1 2014($0.05)($0.05)$13.65 million$14.12 millionViewN/AView Earnings Details
2/28/2014Q413($0.04)($0.02)$15.84 million$16.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dyax Corp. (NASDAQ:DYAX)
Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.14 EPS

Dividends

Dividend History for Dyax Corp. (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dyax Corp. (NASDAQ:DYAX)
Insider Trades by Quarter for Dyax Corp. (NASDAQ:DYAX)
Institutional Ownership by Quarter for Dyax Corp. (NASDAQ:DYAX)
Insider Trades by Quarter for Dyax Corp. (NASDAQ:DYAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/10/2015Thomas L KempnerDirectorSell6,000$22.47$134,820.00View SEC Filing  
8/28/2015Thomas L KempnerDirectorSell17,947$23.83$427,677.01View SEC Filing  
8/18/2015Thomas L KempnerDirectorSell18,035$23.83$429,774.05View SEC Filing  
8/13/2015Thomas L KempnerDirectorSell4,848$23.81$115,430.88View SEC Filing  
7/20/2015Henry E BlairDirectorSell50,000$27.05$1,352,500.00View SEC Filing  
6/8/2015David J MclachlanDirectorSell75,000$25.63$1,922,250.00View SEC Filing  
3/6/2015Andrew D AsheEVPSell2,400$15.50$37,200.00View SEC Filing  
3/5/2015Burt A AdelmanCMOSell9,375$15.66$146,812.50View SEC Filing  
3/5/2015George V MigauskyCFOSell5,000$15.86$79,300.00View SEC Filing  
3/5/2015Gustav ChristensenCEOSell6,250$15.86$99,125.00View SEC Filing  
2/26/2015Andrew D AsheEVPSell1,500$15.34$23,010.00View SEC Filing  
1/2/2015Burt A AdelmanCMOSell75,000$14.05$1,053,750.00View SEC Filing  
12/5/2014Thomas L KempnerDirectorSell14,764$13.79$203,595.56View SEC Filing  
11/21/2014Thomas L KempnerDirectorSell100,000$13.20$1,320,000.00View SEC Filing  
9/12/2014Thomas L KempnerDirectorSell12,400$11.00$136,400.00View SEC Filing  
8/26/2014Thomas L KempnerDirectorSell37,000$10.39$384,430.00View SEC Filing  
8/19/2014Thomas L KempnerDirectorSell113,755$9.67$1,100,010.85View SEC Filing  
8/7/2014Thomas L KempnerDirectorSell33,190$9.25$307,007.50View SEC Filing  
6/13/2014George V MigauskyCFOSell16,000$8.26$132,160.00View SEC Filing  
3/5/2014Henry BlairDirectorSell150,000$10.46$1,569,000.00View SEC Filing  
3/3/2014Andrew AsheEVPSell30,000$10.00$300,000.00View SEC Filing  
3/3/2014Burt AdelmanCMOSell55,000$9.68$532,400.00View SEC Filing  
2/26/2014Andrew AsheVPSell2,723$10.10$27,502.30View SEC Filing  
12/5/2013Thomas KempnerDirectorSell400,000$8.37$3,348,000.00View SEC Filing  
8/13/2013Andrew AsheVPSell32,500$4.30$139,750.00View SEC Filing  
5/16/2013Marc D KozinDirectorBuy22,971$2.46$56,508.66View SEC Filing  
2/25/2013George V MigauskyCFOSell4,275$3.28$14,022.00View SEC Filing  
2/25/2013Ivana MagovcevicCOOSell4,015$3.24$13,008.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Dyax Corp. (NASDAQ:DYAX)
Latest Headlines for Dyax Corp. (NASDAQ:DYAX)
Source:

Social

Chart

Dyax Corp. (DYAX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.